How can formulation scientists make more thoughtful decisions without becoming thermodynamics experts? That’s the question that led to SOLCALC. SOLCALC is an Excel-based add-in designed specifically for drug formulation applications. With the proper training, this software transforms PC-SAFT modeling from a powerful theory into a formulation tool that scientists can use confidently. Below, we explain […]

Can predictive modeling replace years of drug stability testing? This case study explores how researchers of Janssen Pharmaceuticals, TU Dortmund University, and amofor teamed up to tackle one of the most persistent challenges in ASD formulation: accurately predicting shelf life without waiting years for empirical data. The team developed a physics-based approach that combines long-term

Creating effective and stable drug formulations shouldn’t be guesswork. It’s deeply rooted in science. Yet, many formulators still rely on labor-intensive experimental trial-and-error approaches to probe solubilities and mitigate crystallization risks. Worse, without a deep understanding of why a formulation works, scientists can’t predict how changes might affect its bioavailability, shelf life, or manufacturability. So,

Spray drying is a leading technique for manufacturing amorphous solid dispersions (ASDs). At its core lies atomization: you dissolve an active pharmaceutical ingredient (API) and polymers in a solvent mixture, feed this solution into a spray dryer, and collect the resulting powder. But anyone who’s run a spray drying campaign knows that it’s an extremely

As pharmaceutical research pushes towards previously “undruggable” targets, the challenge often boils down to one key issue: complex drugs with poor water solubility. To overcome this obstacle, scientists typically turn to Amorphous Solid Dispersions (ASDs) to enhance solubility and bioavailability. However, these systems introduce their own complexity. One major hurdle is the so-called “limit of

Dear Partners and Clients, As we wrap up 2024, we want to take a moment to reflect on what an exciting and fruitful year it has been for amofor. Together with our partners, we’ve made tremendous strides in advancing in-silico formulation development and pushing the boundaries of pharmaceutical science. Our continued efforts to develop better

Release profiles are at the heart of successful formulations. However, drug formulation scientists struggle with them. Weeks of trial-and-error experiments. Unpredictable outcomes. No mechanistic understanding.amofor is now changing this. Formulators can use a drug release forecasting tool that delivers unprecedented accuracy, enabling better formulations in record time and at reduced cost. The Challenge of ASD

Physics-based simulations enhance the precision of pharmaceutical drug formulation. This blog presents a proof-of-principle study conducted in collaboration between amofor and Boehringer Ingelheim. This project aimed to evaluate the feasibility of shifting from spray-drying to hot-melt extrusion (HME) in producing amorphous solid dispersions (ASDs), focusing on in vitro and in vivo performance comparisons. Traditionally, spray-drying

This October amofor is making our debut at the AIChE Annual Meeting in San Diego. From October 27 to 31, 2024, we will join thousands of professionals at the world’s largest chemical engineering conference to shape the future of drug formulation. We look forward to connecting with drug formulators and industry professionals! Why Attend AIChE and Connect with amofor?

In the last five years, amofor has rapidly transformed from a German academic start-up to a highly innovative force revolutionizing drug formulation with physics-based in silico modeling. On this occasion, the two founders, Christian Lübbert and Gabriele Sadowski, shed some light on the origins and driving forces behind amofor. Who is behind this company, and what